7TZ7

PI3K alpha in complex with an inhibitor

7TZ7 の概要

• エントリーDOI: 10.2210/pdb7tz7/pdb
• 分子名称: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, Isoform 3 of Phosphatidylinositol 3-kinase regulatory subunit alpha, (4S,5R)-3-[2'-amino-2-(morpholin-4-yl)-4'-(trifluoromethyl)[4,5'-bipyrimidin]-6-yl]-4-(hydroxymethyl)-5-methyl-1,3-oxazolidin-2-one, ... (4 entities in total)
• 機能のキーワード: inhibitor, heterodimer, transferase, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 160627.61

構造登録者

Knapp, M.S.,Tang, J. (登録日: 2022-02-15, 公開日: 2022-05-18, 最終更新日: 2023-10-18)

主引用文献

Fairhurst, R.A.,Furet, P.,Imbach-Weese, P.,Stauffer, F.,Rueeger, H.,McCarthy, C.,Ripoche, S.,Oswald, S.,Arnaud, B.,Jary, A.,Maira, M.,Schnell, C.,Guthy, D.A.,Wartmann, M.,Kiffe, M.,Desrayaud, S.,Blasco, F.,Widmer, T.,Seiler, F.,Gutmann, S.,Knapp, M.,Caravatti, G.
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
J.Med.Chem., 65:8345-8379, 2022

PubMed Abstract: Balanced pan-class I phosphoinositide 3-kinase inhibition as an approach to cancer treatment offers the prospect of treating a broad range of tumor types and/or a way to achieve greater efficacy with a single inhibitor. Taking buparlisib as the starting point, the balanced pan-class I PI3K inhibitor (NVP-CLR457) was identified with what was considered to be a best-in-class profile. Key to the optimization to achieve this profile was eliminating a microtubule stabilizing off-target activity, balancing the pan-class I PI3K inhibition profile, minimizing CNS penetration, and developing an amorphous solid dispersion formulation. A rationale for the poor tolerability profile of in a clinical study is discussed.

PubMed: 35500094
DOI: 10.1021/acs.jmedchem.2c00267

実験手法

X-RAY DIFFRACTION (2.41 Å)